Lipocine
LPCN
19 hedge funds and large institutions have $4.38M invested in Lipocine in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
78% more capital invested
Capital invested by funds: $2.46M → $4.38M (+$1.92M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
6% more funds holding
Funds holding: 18 → 19 (+1)
1.03% more ownership
Funds ownership: 8.91% → 9.94% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$349K |
| 2 |
BlackRock
New York
|
+$92.2K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$82.3K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$74.2K |
| 5 |
Renaissance Technologies
New York
|
+$28.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$217K |
| 2 |
Two Sigma Advisers
New York
|
-$80.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.77K |
| 4 |
OPTFSNA
Old Point Trust & Financial Services N A
Newport News,
Virginia
|
-$307 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$218 |
LPCN Hedge Fund Activity: Q2 2024 in Review
19 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2024, worth a combined $4.38M — up 78% from $2.46M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LPCN positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.
The largest buyer was UBS Group, adding an estimated $349K. The largest seller was Susquehanna International Group, cutting an estimated $217K.
- 19 institutional investors held Lipocine (LPCN) as of Q2 2024, up from 18 in Q1 2024.
- Funds reported $4.38M of Lipocine stock for Q2 2024, up 78% quarter-over-quarter.
- 4 funds opened new Lipocine positions in Q2 2024 and 3 closed out, a net change of +1 holder.
- The largest Lipocine buyer in Q2 2024 was UBS Group, an estimated $349K added.
- The largest Lipocine seller in Q2 2024 was Susquehanna International Group, an estimated $217K sold.
Based on aggregated 13F filings for Q2 2024.